Ketamine Transdermal Patch Abuse Deterrent Matrix
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for major depressive disorder (MDD) and neuropathic pain, such as antidepressants and ketamine administration, face limitations including delayed onset, limited efficacy, adverse side effects, and high abuse potential, with existing delivery methods like IV and intranasal routes causing rapid plasma concentration spikes and frequent dosing needs.
Innovation Solution
Transdermal delivery devices comprising ketamine with abuse deterrent agents, providing controlled and prolonged exposure, improved pharmacokinetic properties, and flexibility in dosage and duration, which reduce adverse side effects and abuse risk by incorporating ketamine into a polymeric matrix with skin permeation enhancers and additional deterrents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Speed
If IV or intranasal ketamine administration is used, then rapid antidepressant effect is achieved, but plasma concentration spikes occur causing adverse side effects and abuse potential
Solution Approach 1:
The patent changes the delivery parameters by using transdermal administration instead of IV or intranasal routes, maintaining rapid onset while controlling plasma concentration levels to reduce side effects and abuse potential
Solution Approach 2:
The patent introduces a transdermal delivery system as an intermediary between the ketamine and the bloodstream, using skin permeation enhancers and polymeric matrices to control absorption rate and avoid concentration spikes
2Reliability
If conventional antidepressants are used, then treatment coverage is provided, but delayed onset of action occurs taking weeks to months
Solution Approach 1:
The patent changes the pharmacokinetic parameters by using transdermal delivery to achieve rapid onset within hours, compared to weeks or months for conventional antidepressants, while maintaining sustained therapeutic levels
3Duration of action of moving object
If transdermal delivery is used, then controlled prolonged exposure is achieved, but skin permeation barriers must be overcome
Solution Approach 1:
The patent uses skin permeation enhancers and polymeric matrices as intermediaries to facilitate ketamine penetration through the skin barrier while maintaining controlled release over extended periods
Solution Approach 2:
The patent employs composite formulations combining ketamine with polymeric matrices and permeation enhancers to achieve both sustained release and effective skin penetration
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The transdermal delivery system achieves sustained plasma concentrations for extended periods, minimizing side effects and abuse potential, while offering improved convenience and compliance, with reduced risk of drug toxicity and increased therapeutic efficacy for MDD and pain management.
Implementation Method 1
transdermal delivery devices comprising ketamine... The transdermal delivery system achieves sustained plasma concentrations for extended periods
Implementation Method 2
incorporating ketamine into a polymeric matrix with skin permeation enhancers... providing controlled and prolonged exposure
Data Source
AI summary
The present invention is directed to a transdermal delivery device comprising ketamine and formulations thereof. The present invention is also directed to a transdermal delivery device comprising ketamine for the treatment of major depressive disorder (MDD) and/or pain. The present invention is further directed to a transdermal delivery device comprising ketamine and abuse deterrent agents.